By Dr. Svea Grieb, Kai Touw and Dan Kopec
The internet of things and robotics are already the working standard in fast-adapting industries. These technologies are now also being implemented in the biopharma industry, which is more conservative due to strong regulations and intrinsically complex processes. How is this change going to proceed and how does it change the industry? Does it provide a bigger benefit than its risk? We asked three experts for process analytical technologies, automation and data analytics from Sartorius about their view on the future of bioprocessing.